Speaker

David Ge CEO & President, Apostle Inc

Dr. David (Dongliang) Ge is CEO & President of Apostle Inc (http://apostlebio.com), a Silicon-Valley-based biotechnology company developing a novel AI (Artificial Intelligence)-enabled NanoDiagnostics (AID) Technology for cancer detection at the early stage and other diagnosis and treatment of human diseases. Dr. Ge is also appointed as member of U.S. NIH NHGRI Special Emphasis Panel, and Adjunct Assistant Professor at Duke University. Dr. Ge has had extensive experience in leadership roles in both American and Chinese biotechnology industry. Prior to Apostle, he was President of BioSciKin Co., Ltd., a China-based biotechnology company focusing on diagnostics, drug innovation, incubating, investing and licensing. Before BioSciKin, he was Director of Bioinformatics at Gilead Sciences, where he provided leadership to the corporate bioinformatics group and provided strategic input to the precision medicine infrastructure and process. Before Gilead, he was appointed as Assistant Professor of Medicine, Biostatistics and Bioinformatics at Duke University School of Medicine. He received his PhD of Biostatistics and Genetic Epidemiology from Chinese Academy of Medical Sciences in 2004. Dr. Ge was named by the U.S. Genome Technology magazine as one of the “rising stars” in 2009 and by the U.K. Phacilitate as one of the "Top 50 Most Influential People in Big Data" in 2015. At Gilead, he and his colleagues contributed to the clinical development of Sofosbuvir, a world-leading anti-HCV drug. His work in discovering the IL28B genetic variants associated with the hepatitis C patients’ response to clinical treatment, published in Nature in 2009, has received over 3000 citations to date. In total, his work, including 5 original articles in Nature and 1 in Science, has received over 16,000 citations.